Vitiligo or alopecia areata Vitiligo, alopecia areata
Conditions
Interventions
Treatment is performed with a low-frequency therapy device (JMDN code: 35372000, https://www.std.pmda.go.jp/scripts/stdDB/JMDN/stdDB_jmdn_resr.cgi?Sig=1&Select=1&jmdn_no= 2867&kjn_no=10123). Bathing s
Sponsors
Ujiie Hideyuki
Eligibility
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria are eligible (i) Patients who are at least 18 years of age at the time of consent. (ii) Patients who have been diagnosed with vitiligo or alopecia areata based on clinical symptoms or pathological examination. (iii) Patients who, after receiving sufficient explanation of their participation in this study, are able to actively understand the consent document on their own initiative and have given their free written consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria Patients with any one of the following conditions shall be excluded from the study (1) Patients with a history of unstable vascular or neoplastic brain lesions (2) Patients receiving concomitant vagus nerve stimulation therapy (3) Patients with a history of severe cardiovascular disease (i4) Pregnant or lactating (5) Patients with skin hypersensitivity and a history of skin symptoms caused by metal or other substances. Translated with DeepL.com (free version)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in symptom severity rating scale (VASI score for vitiligo and SALT score for alopecia areata)) from study entry point to 52 weeks post-treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| (i) Whether or not any adverse events occurred during infrasound therapy. (ii) DLQI scores before and after infrasound therapy (iii) The localization of immune cells before and after the infrasound treatment, the positive expression of molecules induced by inflammation, the intensity of expression, and the presence or absence of disease-related gene variants and their association with the pathological condition. Correlation between the state of inflammation and the expression status of clinicopathological factors and other analyzed molecules. | — |
Contacts
Public ContactYuichi Kojima
Hokkaido University
Outcome results
None listed